Literature DB >> 3214594

Gastrointestinal iodine-131-meta-iodobenzylguanidine activity.

O Geatti1, B Shapiro, B Shulkin, R Hutchinson, J C Sisson.   

Abstract

Radioactivity in the colon during 131-I-meta-iodobenzylguanidine (MIBG) scintigraphy may obscure or be mistaken for tumor uptake. Fecal excretion of radioactivity was examined in eight patients following therapeutic 131-I-MIBG administration (123-218 mCi, 4.551-8.066 GBq) and was found to be 0.02-1.93% of the administered dose. Semiquantitative grading of colonic activity on scintigraphy was inversely related to fecal excretion. An additional patient with marked colonic activity was studied before and after an enema: all visible gut activity was evacuated. We conclude that radioactivity in the colon seen in 131-I-MIBG scintigraphy is due largely to gut excretion of 131-I and is not due to 131-I-MIBG uptake in the autonomic innervation of the gut. Laxatives and enemas are suggested for patients in which such gut radioactivity may lead to difficulties in interpretation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3214594

Source DB:  PubMed          Journal:  Am J Physiol Imaging        ISSN: 0885-8276


  2 in total

1.  Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

Authors:  Steven G DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P Mosse; John M Maris; Denice Tsao-Wei; Araz Marachelian; Judith G Villablanca; Katherine K Matthay
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

Review 2.  Nuclear medicine and multimodality imaging of pediatric neuroblastoma.

Authors:  Wolfgang Peter Mueller; Eva Coppenrath; Thomas Pfluger
Journal:  Pediatr Radiol       Date:  2012-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.